Ge Long Hui A P P·2025-11-27 09:14Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the listing application of Acetate Prednisone, which is primarily used for allergic and autoimmune inflammatory diseases [1] Group 1: Product Approval - The approval notification for Acetate Prednisone indicates its potential market entry, which may enhance the company's product portfolio [1] - The drug is commonly used for conditions such as active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, and various adrenal cortical insufficiencies [1] - Acetate Prednisone is also utilized in the comprehensive treatment of certain infections, broadening its therapeutic applications [1]